Partnering Week

October 14

In person in Paris, Morning Bourse
The program will emphasize pitches and exchanges! A friendly and relaxed atmosphere!

October 16 & 17

Join us on our online platform for two days of exclusive meetings with our startups, and seize the opportunity to initiate new partnerships!
Don’t miss this opportunity to discover a wealth of innovations!
Major companies, investors, to register, click here >>

Already registered?
Click here to set up your appointments now!

Investor

Marion Bazille, Program Director | Big Idea Ventures
“ Partnering Week is an excellent event for us to meet qualified startups incubated by Genopole. We know these are startups with very advanced technologies, giving them a strong competitive advantage and numerous barriers to entry. We have already invested in several startups that have passed through Genopole. That’s why we will be participating in this new edition!”

Major Company

Chloé Leprêtre, Global Head R&D Search & Evaluation, R&D External Innovations | Servier
“Partnering Week is an opportunity for us to keep abreast of the development of start-ups supported by Genopole in the field of pharmaceuticals, and for our part, to share information on the evolution of our therapeutic areas. Oncology remains a major focus for Servier, which is also very interested in neurology and precision medicine supported by new artificial intelligence technologies. We’re on the lookout for innovations. We know that the companies accelerated by Genopole are well constituted and have well thought-out projects. That’s why we’ll be taking part in Partnering Week once again“.

Startup

Rachel Morra, EMBA, Head of Scientific Partnerships and Alliances, BD | Enterome
“Participating in Partnering Week in October 2023 allowed us to resume discussions with potential partners already known but also to establish new promising contacts with companies we met during subsequent events, with whom we are currently pursuing discussions. The more intimate format of Partnering Week makes it easier to get appointments with key players in the pharmaceutical industry.”

🚨 Registration is open 🚨

Registration is free but mandatory to participate in the event in Paris and access the meeting platform.

Please complete the form >>

Venue – October 14 in Paris:

Morning Bourse
Metro: Bourse 3 – 9 – 8
4-6 place de la bourse
75002 Paris

📍Access map >>

#FOODTECH

• Auralip

  AuraLIP Low Impact Protein creates fermented ingredients for meat alternatives, 100% ULTRA natural customizable in taste and texture.

  Highlights:

  • Patent filed
  • Non-dilutive funds received and fundraising launched
  • Letter of intent signed

  

   

• DNTech

  DNTech develops a sensitive, portable kit that allows the detection of pathogens from the sample to the result within two hours. Patentable technology is based on innovative molecular biology methods.

  Highlights :

  • Forum labo start-up challenge 2023 and Boston women entrepreneur program winners
  • Molecular biology results validated
  • Pre-design of the analyzer completed
• FUNGU’IT

  At Fungu’it, our mission is to make industrial food production healthier, more sustainable, and accessible by upcycling plant by-products through fermentation to create a new generation of aromas. Our unique solid-state fermentation process transforms by-products into high-value aromatic ingredients.

  We have developed ingredients for the plant-based meat market as well as for the cocoa market, with our first ingredient already commercialized.

  

• Mycellium technologies

  MYCTECHS’ innovation reduces our meat consumption with tasty fungus mycelium based foods.

  This is achieved through our innovative technology that rehabilitates the benefits of fermentation and promotes a circular economy by giving a second life to agro by-products.

  

• Nutropy

  

  Nutropy is a French B2B company that enables the next generation of cheese & dairy products using its precision fermentation technology. More specifically, Nutropy develops an animal-free plug & play milk replacement for large scale dairy applications.

  We produce milk proteins and fatty acids identical to those produced by cows to enable the production of cheeses that taste as good as conventional cheese but are more sustainable, healthier and better for the animals.

   

• Onima.bio

  Onima.bio upcycles brewers’ yeast through a unique de-bittering process to produce a sustainable super-ingredient full of proteins for food manufacturers.

  

• So Sweet

  So Sweet produces a new generation of sweet ingredients from plant proteins extracted through an innovative process to address sugar reduction and taste improvement challenges for food manufacturers.

  

• Standing Ovation

  Standing Ovation is developing cheese using precision fermentation caseins.

• The VERY Food Co.

  Established in 2022, French company The VERY Food Co. has taken on the mission of decarbonizing the agri-food sector by replacing milk and eggs used as ingredients with functional proteins of plant origin.
  A driving force for change, The VERY Food Co. develops solutions that can be easily integrated into existing processes for food manufacturers and foodservice professionals.

  

• Ÿnsect

  Ÿnsect is the leading specialist in the production of insects for domestic animals, farmed fish, plants and, tomorrow, humans.

  

#BIO-BASED

• ABOLIS Biotechnologies

  Abolis  is delivering high-impact innovations in biotechnologies, supporting industries in their transition to a more sustainable model by building a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms.

  Highlights: 

  • Abolis expands outside Europe after signing 2 contracts in the United States.
  • Microbiome Studio, the company’s subsidiary dedicated to the Microbiome, moves into Station F, in the heart of Paris.

  

• ALGA BIOLOGICS

  ALGA BIOLOGICS offers sustainable and eco-responsible production of antibodies and recombinant proteins via microalgae.
  Compared to mammalian cells, microalgae reduce production costs, increase efficiency and safety while decarbonizing production.

  ALGA BIOLOGICS is now looking for investors and business partners to help us develop our activities in human and animal health and cosmetics.

• Algentech

  Algentech is an industrial biotech company, specialized in synthetic biology, which has developed a proprietary technological platform for the valorization of bio-based components for industry. It relies on the natural power of plants to sustainably transform industrial practices and respond to the global challenges of climate change. Algentech is positioned as a partner, supplier of value-added biobased ingredients for multisectorial applications. We use the natural power of plants to provide best in class biobased products for pharmaceutical, cosmetic and biomaterial industry sectors.

  Highlights: 

  • Several ongoing collaborations with market leaders
  • 7 patent families
  • Technology published in Nature Plants

• Altar (A Lesaffre company)

  Created in 2017, Altar is a biotech company specialized in automated microbial fluidics. She operates a directed evolution platform for microorganisms at Genopole as part of research services or proprietary projects aimed at developing microorganisms of industrial interest.Following Lesaffre’s acquisition of the company in October 2024, the Altar team was integrated as a new ALE department within Lesaffre.

  

• STH BIOTECH

  

  STH BIOTECH  unlocks the access to rare cannabis active compounds using plant biotechnology and synthetic biology to develop innovative active ingredients and APIs for industrials.

   

• SYNANTHRA

  Synanthra produces sustainable green ammonia through innovative bio-synthetic processes using photosynthetic bacteria.

  Our scalable and cost-effective solution offers high market potential while addressing climate change with net-negative CO2 emissions.

  We aim to revolutionize ammonia production by offering an eco-friendly alternative that meets the growing global demand in both industrial and agricultural sectors. We are currently raising funds and looking for strategic partnerships.

#GREENTECH

• 5 H 45

  5 H 45 is pioneering a new category of hair products that utilize patented
  protein-based nanofilm technology to functionalize the hair’s surface,
  offering the only alternative to the toxic chemicals commonly used in relaxing, perming, and dyeing. Beyond cosmetic uses, the functionalized nanofilm enables us to enter the drug delivery market, offering treatments for conditions such as lice and hair loss.

• AGDIA EMEA

  Agdia Emea optimizes diagnostic solutions for plant pathogens and genetically
  modified organisms (GMOs) based on immunological and molecular techniques.  Our diagnostic kits are sensitive, reproducible, robust and reliable and are aimed at seed professionals, horticulturists, and plant diagnostic and research laboratories.

• AMATERA BIOSCIENCES

  Amatera Biosciences is on the mission to sustain perennial crops. To do so, our non-GMO breeding platform accelerates the natural evolution, the selection and the crossing of plants directly at a cellular level. Our first application is on coffee, before expanding to other perennial crops threatened by climate change and massive diseases, such as cacao, grapes and bananas.

  

• BIOMEDE

  BIOMEDE selects and markets seeds from plants that hyperaccumulate trace metals (TMEs), removing them naturally from the soil.

  

• BLUE 2 (Project)

  Blue 2 enables manufacturers to earn money while decarbonising their business using microalgae. The CO2 captured is converted into useful biomass, and our customers save on carbon tax while selling their products at a premium green price.

• GLOBAL BIOENERGIES

  Global Bioenergies substitutes products of fossil origin with products of natural origin. In their quest for naturalness without compromising on performance, the cosmetics players are the Company’s first customers.
  By 2027, the Company will be operating its innovative process in a large-scale plant.
  By 2030, the Company plans to become a leader in the huge emerging market for sustainable aviation fuels, in order to fight against global warming.

  Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 – ALGBE).
  L’Oréal is its largest shareholder, with a 13.5% stake.

  

• LEAFY

  Leafy makes available new diagnostic technologies and its expertise in phytopathology, plant and animal genetics for the benefit of the agricultural sector. These simple, fast and efficient detection kits and services allow a better and more moderate use of phytosanitary treatments and the acceleration of the creation of new varieties for a better respect of the environment and human health.   

   

• MAISON M

  Maison M designs the first range of innovative, personalized and responsible cosmetics. ECLIPS is a lipstick with 3 customized shades thanks to AI.

  Highlights:

  • Technologies protected by 2 patents
  • Funds raised
  • 350 pre-sales of Eclips lipstick

  

• MICROXPACE

  microXpace offers patented probiotic solutions specifically designed against parasitic diseases in aquaculture. Our cutting-edge technology is uniquely effective in managing sea lice infestations, a significant challenge in the salmon farming sector.

   

• NOVOBIOM

  Novobiom harnesses the potential of fungi to usher in a sustainable future by transforming industrial waste streams into high value biosurfactants through a revolutionary upcycling process. Initially focused on biological treatment solutions for polluted land, Novobiom has developed its technological platform in the bioproduction sector. Our fungal biorefinery platform encompasses a holistic approach, integrating the fungal strain selection, bioinformatics, biological digital twinning combined to AI machine learning processes optimisation, and solid-state fermentation techniques.

• PLANTIK BIOSCIENCES

  Plantik Biosciences develops innovative technologies to accelerate plant engineering, based on new genome-editing tools.

  

• PROTEME

  Proteme is a French impact green chemistry company which relies on a versatile encapsulation technology platform and has set itself the mission of replacing synthetic chemistry with natural alternatives. The first application is a substitute for synthetic phytosanitary products applied after harvest to fruits & vegetables: it is a food coating which extends their shelf life and protects them against storage diseases.

  

• WATCHFROG

  Watchfrog is dedicated to the endocrine activity assessment of chemical, cosmetic, and water samples.

  Highligths:

  • Exclusively focused on endocrine activity evaluation
  • Patented method developer
  • TG OCDE XETA N°.248 and RADAR N°.251

  

#DIAGNOSTIC

• CELL ENVIRONMENT

  Cell Environment develops high-throughput cytogenomic assays combining detection of chromosomal instability and telomere dysfunction for personalized medicine and precision oncology. Our technology is based on labelling kits and an analysis platform. This innovative approach is sensitive with rapid analysis and allows unique low cost.

  

• CGenetix

  CGenetix is developing a new non-invasive in vitro medical device to quantify organ damage during a pathological process such as transplant rejection. Focusing first on kidney transplantation, we plan to become in the next decade one of the European leaders in cfDNA for the medical follow-up of transplant patients.

   

• Enalees

  Enalees develops and produces molecular diagnostic tests for infectious diseases that can be used directly by veterinary professionals in clinics. Using the latest generation molecular technology, the tests combine specificity, sensitivity, and rapid results (30 minutes).

  The company’s expertise covers every stage from test design to kit manufacture and control. Enalees offers more than 50 tests via 2 ranges: Epona (horses) and Astéria (dogs and cats), which detect more than 20 infectious diseases. The company can produce up to 85,000 freeze-dried tests per month.

  

• Endogene.Bio

  Endogene.Bio is a biomarker discovery company for female health that specializes in epigenetic markers in menstrual blood. Our first product is an endometriosis diagnostic test. We are looking for partners for drug response use cases of our technology.

  

• Exosome Analytics

  Exosome Analytics detects the most rare exosomes towards personalized clinical medicine.

  Highlights: 

  • Development of a diagnostic platform for the early detection of ovarian cancer.
  • Pilot tests performed on urine samples demonstrated 100% sensitivity of our platform (compared to 43% for the CA125 serum test currently used).
  • We are starting the preclinical study.

  

• Felome

  Now more than ever, pets are part of our family. People are curious about the ancestry of their pets and their risk for disease.

  FELOME uses the advantages of next-generation sequencing to offer DNA analysis for companion animals that is accessible and affordable for consumers.

  

• INNOVHEM

  INNOVHEM is developing tools to improve the management of sickle cell disease patients. These diagnostic tools will be used by physicians to help monitor a patient’s disease. Based on new biomarkers combined with artificial intelligence analysis, these tools will enable personalized management.

  

• PREDIDIAB

  PREDIDIAB proposes to develop tests capable of integrating all individual, environmental and heritable factors, to predict with good accuracy the onset of type 2 diabetes in subjects still in perfect apparent health, the age of onset, the form of diabetes and its evolution. This kind of prediction will enable us to propose a personalized prevention strategy. The tests are based on several patents filed or in preparation by academic players CERITD and UMR8199.

#HEALTHTECH

• AB Science

  AB Science specializes in the development of highly specific tyrosine kinase inhibitors to treat diseases with high medical needs in the fields of oncology, chronic inflammatory diseases and neurodegenerative diseases.

  

• Abcell-bio

  Abcell-bio  specializes in the isolation of human hematopoietic stem cells and primary cells from cord blood.
  With the ability to customize and adapt our offers to the needs of our customers, we produce high quality human primary cells (purity and viability) to simplify and speed-up research. Abcell-bio is also an R&D laboratory, as such, we want to help generate the innovation of tomorrow.
  We think that cell isolation and cell culture innovations could move forward the medicine of tomorrow.

  Highlights:

  • For over 15 years, Abcell-bio has gained expertise in the field of hematopoietic stem cells and primary cells
  • Abcell-bio has developed a unique french maternity wards network which ensures a secure and reliable sourcing of cord blood.
  • Since 2028, Abcell-bio is part of BioNordic, an international Danish group dedicated to production and distribution of products for biotechnology and food industry.

  

• Adlin Science

  ADLIN Science is a mission-driven company that develops a Digital Research Environment (science software) that supports your multidisciplinary R&D teams on a daily basis (biotechs/Techbios/agrotechs).
  Our Environment allows you to manage your projects and operational/scientific processes (interoperability and traceability of data/protocols, workflows, bioinformatics/biostat tools, no-code data visualization, dashboards, multisite/multidisciplinary collaboration, …).
  We are already actively working with biotechs/Techbios/CRO/agrotechs and, more broadly, we have developed partnerships with public institutes (INSERM, CHUs, RHUs, …) that use our solutions and services.

  Highlights:

  • ADLIN has been awarded by 2 major technological contests in 2022 (iNov & iLab BPI France), confirming our technological positioning.
  • In 2022 and 2023, ADLIN has established strong partnerships with top-tier public institutes and IHUs (such as INSERM, Imagine, Share4Kids network…).
  • In 2023, ADLIN acquired LinkInnov (a marketplace dedicated to fast & easy intermediation of public researchers with the industry for expertise missions), reinforcing its position as a trusted third-party.
• AGS Therapeutics

  AGS Therapeutics develops Extracellular Vesicles from Microalgae (MEVs) as a universal delivery system for innovative therapeutics, vaccines and gene therapy.
  MEVs can be efficiently loaded with a diversity of payloads (mRNAs, siRNAs, oligos, plasmids, peptides, proteins).

  AGS Therapeutics has a pipeline of two leads products:

  • AGS-1010 for the treatment of wAMD (retinal disorder),
  • AGS-2010 for the treatment of an inflammatory intestinal diseases (IBD).

  AGS’IP dominates the field of extracellular vesicles from microalgae for medical and cosmetics use.

• BioHive

  BioHive designs and analyzes the first lab-grown skin model featuring a hair follicle, fully customizable for the pharmaceutical and cosmetic industries. This innovative model enables more precise research and reliable testing. BioHive is currently launching its first standard model and is in the process of raising funds. The company is seeking clients and investors to accelerate its growth and expand the application of its technologies.

  

• bYoRNA

  

  bYoRNA develops more efficient and safer mRNAs to power the next wave of RNA medicines.
  Thanks to a disruptive green production technology, bYoRNA has engineered yeast cells to produce human-like mRNA, more efficient, safer and easier to manufacture, while preserving the environment. We can produce 7,000-nucleotide mRNA at the same price than shorter ones, making easier to produce Cas9 gene editing mRNA or self-amplifying mRNA.

  Highlights:

  • we leverage a french patent to develop the technology in the EU and the US,
  • we have already produced a few milligrams of mRNA in living cells,
  • we have signed co-development agreements with key industry players.

• Enterome

  Enterome is developing a new generation of immunomodulatory drugs for the treatment of cancer and autoimmune diseases. The company is open to R&D partnerships with players in the pharmaceutical industry in order to advance its immuno-oncology portfolio, with 4 products in clinical stage, as well as its projects in allergy and autoimmunity.

  Highlights:

  • Established a partnership with Nestlé Health Science in inflammatory diseases and food allergy.
  • Since its inception, the company has raised a total of €116 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.

  

• Genethon

  Généthon researches and develops innovative therapies for rare genetic diseases, particularly neuromuscular ones. Généthon is a non-profit laboratory with the objective of providing patients with treatment as quickly as possible. Its mission is to develop treatments that change the lives of patients suffering from rare genetic diseases and to eradicate these conditions. To accelerate the development of its therapies and their availability to patients, Genethon regularly partners with pharmaceutical laboratories and biotech companies that can provide complementary expertise and necessary resources.

  Highlights:

  • A first drug, to which Genethon contributed, has been approved for spinal muscular atrophy.
  • Généthon co-founded the Genother biocluster as part of the “Biocluster” call for expressions of interest under the Plan France 2030.

  

• Genosafe

  Genosafe offers unique expertise in the development and validation of quality
  control tests for preclinical and clinical batches of gene therapy vectors or cell therapy products.

• Hybrigenics Services

  Hybrigenics Services offers life science R&D Services and Contract research using innovative screening technology platforms to identify and characterize protein interactions, to support drug discovery with elucidation of the mechanism of action of drug candidates, and to select, validate and optimize synthetic single domain antibodies.

  Highlights:

  • 3000 customers and collaborators worldwide in various life science sectors (pharma, agro, cosmetic, fundamental research)
  • The most comprehensive Y2H-based screening platforms with the largest collection (135+) of highly complex cDNA libraries – 45 species, exhaustive screening, bioinformatics.
  • The most published humanized, synthetic and naïve VHH library to select nanobodies – animal free technology.

  

• IKTOS (ex-Synsight)

  Iktos,founded in Paris in 2016, is a leader in AI for drug discovery (small molecule design and retrosynthesis). Iktos has built a unique platform combining AI (Makya & Spaya SaaS platforms) and automation (Iktos Robotics lab), that accelerates the drug discovery process and reduces it to less than 2 years. Recognized for its collaborations with pharmaceutical companies, Iktos has recently initiated an in-house pipeline of therapeutic programs that will reach drug candidates stage by 2025.

  

• InnoBioMil

  InnoBioMil manufactures premium-class cell culture media and feeds ready to be provided to our national and international customers.
  All our products are produced to fulfill the highest regulatory biopharmaceutical requirements.

  Since our opening, we have expanded our manufacturing capabilities and capacities constantly.

  We pride ourselves with our quality management and quality assurance systems and deliver the best quality services to our clients.

  

• Ispiron

  At Ispiron, our mission goes beyond revolutionizing AAV production; we are redefining the entire landscape of biotherapeutics, including CAR-T cells, antibodies, and recombinant proteins, with our cutting-edge technology.
  Standing at the forefront of biotechnological innovation, our latest bioreactor design is engineered to transform the cell culture process, delivering unprecedented speed, efficiency, and cost-effectiveness. This state-of-the-art system is meticulously crafted for scalability, ensuring seamless industrial manufacturing that sets new standards for reliability and performance.
  Our bioreactor is not merely a tool—it’s a game-changing innovation in biologics production. With advanced automation, real-time monitoring, and intelligent process control, we empower researchers and biotech companies to fast-track the development of life-saving therapies, bringing them to market more rapidly and at a lower cost.
  For visionary investors and strategic partners, Ispiron represents more than just a leap forward—it’s the future of biomanufacturing. Our technology is poised to lead the next era of therapeutic breakthroughs.

• Kyron.Bio

  Kyron.bio’s proprietary glycan engineering technology is pioneering a novel era in monoclonal antibody development. Our approach unlocks the possibility to use glycans in therapeutic design and has demonstrated remarkable efficacy in reducing severe immunogenic responses to a therapeutic. This is the first time such an approach has been taken, and kyron.bio’s unique glycan engineering strategy is set to open up a new design space for monoclonal antibodies.

  

• Lamark Biotech

  Lamark Biotech develops extra-stable formulations of biotherapeutics for age-related macular degeneration, antivirals and cancer.

  

• New England Biolabs

  Founded in the mid-1970s, New England Biolabs® (NEB) is the leader in the discovery, production and customization of high-quality enzymes for molecular biology applications, including NGS, RT-(q)PCR, RNA science and epigenetics. Based in Paris, the NEB France team is dedicated to NEB’s core values: ethical and collaborative science, top-quality services from R&D to scale-up, and a commitment to the environment.

  Highlights: 

  • Winner of the Innovation Trophy at Forum Labo Paris in March 2023, in the Services category, for NEB Lyo Sciences™: a tailor-made solution for your lyophilization needs.
  • Within the framework of a more ecological and responsible production we have replaced reaction buffers containing BSA with buffers containing recombinant albumin (rAlbumin).
  • NEB is a Certified B Corporation™.

  

• OncoDNA

  OncoDNA specializes in decoding the human genome and provides relevant and rapidly interpretable analyses for academic and private laboratories. We offer researchers and physicians universal and personalized therapeutic guidance tools that enable them to tailor treatments to the patient’s genetic profile.

• Papilio.Bio (Project)

  Papilio.Bio wants to give people the power to live HPV-free by developing an HPV self-test for all genders and an information app to make prevention more accessible and reduce cases of HPV-related cancers.

• PHAIRILAB

  PHAIRILAB innovates with unique biotechnological solutions focused on Colombian biodiversity.
  Our uniqueness lies in transforming natural resources into high-quality health products, principally focus on cancer patients.

  We seek collaborations for funding, R&D, licensing, industrialization, and commercialization of our discoveries.

  Together, we can revolutionize the bioeconomy and provide sustainable and effective health solutions globally. Join us in harnessing the immense potential of nature for the benefit of humanity.

• PHARMING

  Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases.

  Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics that are in early to late-stage development. Pharming is looking for clinical stage opportunities in rare disease indications with high unmet medical need.

• Polytheragene

  Polythéragène develops and commercializes polymers for
  (i) nucleic acids (DNA and RNA) transfer for gene therapy and bioproduction of proteins and
  (ii) for drug delivery.

  Highlights: 

  • Polytheragene is a partner of the Genother biocluster.
  • Polytheragene has developed a new formulation for messenger RNA transfer

  

• SE-Therapeutics

  SE Therapeutics harnesses the power of certain microbial proteins to create innovative treatments.
  We created Self Entering forms of CRISPR/Cas proteins that can penetrate a wide variety of cells, paving the way for a new class of gene-editing therapeutics for the cell and gene therapy industry.
  Our primary mission is to enable access to life saving cell therapies in the field of oncology to millions of people.

  Highlights:

  • Our technology is protected by an international patent.
  • We are developing high value products dedicated to gene and cell therapies.
  • We are fundraising to finance the manufacturing roadmap for SE-CRISPR/Cas9 and GMP formulation.

  

• SEBIA

  Sebia is an in vitro diagnostics company, based in France (Lisses, 91) and established worldwide. Sebia designs, manufactures and markets equipment and reagents for the diagnosis and monitoring of diseases such as multiple myeloma, autoimmune diseases and metabolic disorders, for medical biology laboratories.

  Highlights:

  • Sebia has set up a proteomics platform at Genopole
  • Development of an innovative technology using mass spectrometry to measure residual disease on blood in Multiple Myeloma.

  

• Texcell

  Texcell offers its services in the fields of viral safety and immunological monitoring in full compliance with Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP).

  

• Vitropep

  Vitropep offers a patch of soluble microneedles made of therapeutic peptides for painless, wasteless and effortless injection.

  After applying the patch, the microneedles will melt on contact with the skin and inject the medication or cosmetic painlessly.
  The aim is to improve treatment efficiency and ease of use.

  

• Xentech

  XenTech

  is a science-driven CRO dedicated to advance the development of new anti-cancer therapies from discovery to clinical success by offering access to the most relevant PDX models and services for preclinical evaluation of anticancer therapies and biomarker discovery with:

  • An innovative, wide and unique collection of clinically-relevant PDX models (more than 200) with confirmed clinical correlations
  • A world-class reference breast, prostate and pediatric liver cancer PDX panels
  • Over 40 PDX-derived cellular models
  • Pediatric PDX cancer from solid tumors
  • Specific PDX line from patients with acquired resistance
  • Resources: RNAseq analysis, Whole Exome Sequencing and Tissue Sampling

  to conduct the following translational studies:

  • Drug efficacy
  • Mouse clinical trials
  • in vitro screening
  • Molecular characterization of the models and target ID/Validation

  

• Yposkesi

  Yposkesi, an SK pharmteco company is SK pharmteco’s European manufacturing site. SK pharmteco offers CDMO services for small molecule, Cell and Gene therapy as well as Analytical testing. With a network of seven global, cutting-edge, facilities our capabilities cover the entire product lifecycle, from initial development to commercial manufacturing. We work with customers in a flexible ‘One Team’ approach, prioritizing collaboration, transparency, and trust to make every interaction easy and seamless.

  Highlights:

  2016: Creation of Yposkesi, a Genethon spin-off
  2023: Inauguration of a new viral vector biomanufacturing facility in Corbeil-Essonnes, currently undergoing qualification.
  2024: Start-up of the new bioproduction facility, which will enable us to double our production surface area.

  

• ZEBRAMED (Project)

  ZebraMed’s automated in vivo zebrafish biofoundry revolutionizes drug discovery. Our technology generates a comprehensive picture of drug behavior, analyzing its impact on organs, immune systems, and even human-sourced pathogens, cancers and genetic diseases. This holistic approach, combined with cutting-edge automation and AI, empowers researchers to discover life-saving therapies faster.

  Partner with ZebraMed for:

  • Faster Discovery: Reduce the time from discovery to development, accelerating the path to life-saving treatments.
  • Unmatched Comprehensiveness: Gain a deeper understanding of drug effects with a holistic view, ensuring informed decisions.
  • Reduced Risks: Minimize the risk of late-stage development failures with comprehensive drug evaluation.

  ZebraMed offers unmatched efficiency through automation and precise control with our innovative microfluidic chip (under patenting).
  Join us in accelerating the development of new therapies for patients worldwide.